Results 21 to 30 of about 1,946,248 (285)

Artificial Intelligence-Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae. [PDF]

Adv Sci (Weinh)
Integrated artificial intelligence (AI) ensembles identify highly potent repurposed drugs against Streptococcus pneumoniae. Prospective virtual screening of 6747 drugs uncovers nine active candidates, including thiostrepton. This drug exhibits low picomolar potency and bypasses established resistance in multidrug‐resistant strains, demonstrating an ...
Fitch JS, Ariadi MD, Kwun MJ, Howells L, Hernandez-Hernandez S, Croucher NJ, Ballester PJ.   +6 more
europepmc   +2 more sources

Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases

Drug Design, Development and Therapy, 2013
Minna Allarakhia Department of Management Sciences, University of Waterloo, Waterloo, ON, Canada Abstract: Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The
Allarakhia M
doaj   +1 more source

Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice

Pharmaceuticals, 2023
Paclitaxel is an anticancer agent efficacious in various tumors. There is large interindividual variability in drug plasma concentrations resulting in a wide variability in observed toxicity in patients.
Mirjana Radovanovic, Peter Galettis, Alex Flynn, Jennifer H. Martin, Jennifer J. Schneider   +4 more
doaj   +1 more source

Drug repurposing for cancer therapy

Signal Transduction and Targeted Therapy
Cancer, a complex and multifactorial disease, presents a significant challenge to global health. Despite significant advances in surgical, radiotherapeutic and immunological approaches, which have improved cancer treatment outcomes, drug therapy ...
Wei-Lin Jin, Ming Sun, Hai Huang, Ying Xia   +3 more
core   +4 more sources

Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment

Cells, 2022
Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arrest and repair treatment-induced DNA damage.
Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay, Bryan W. Day, Brett W. Stringer, Paul A. Tooney   +6 more
doaj   +1 more source

A Path to Real-World Evidence in Critical Care Using Open-Source Data Harmonization Tools

Critical Care Explorations, 2023
COVID-19 highlighted the need for use of real-world data (RWD) in critical care as a near real-time resource for clinical, research, and policy efforts.
Smith F. Heavner, PhD, RN, Wesley Anderson, PhD, Rahul Kashyap, MBBS, MBA, Pamela Dasher, BA, Ewy A. Mathé, PhD, Laura Merson, Philippe J. Guerin, MD, PhD, Jeff Weaver, MBA, Matthew Robinson, MD, Marco Schito, PhD, Vishakha K. Kumar, MD, MBA, Paul Nagy, PhD   +11 more
doaj   +1 more source

How drug repurposing can advance drug discovery: challenges and opportunities [PDF]

Frontiers in Drug Discovery
Traditional de novo drug discovery, which typically presents an 11% approval rate from phase I trials and even higher failure rates in fields like neurodegeneration, often requires two to three billion dollars and 10–17 years per new drug.
Luca Pinzi, Nicolò Bisi, Giulio Rastelli   +2 more
doaj   +2 more sources

Drug Repurposing in Cancer

, 2023
The discovery of drug compounds has a long history in drug repurposing, notably by fortuitous findings. It has taken a new path in the creation of novel therapeutics based on existent or authorized drugs in recent years.
Jain, M. S.,, Zhang, Hong,, Pathak, S.,, Banerjee, A.,, Ganesan, H.,, Sun, X.-F.,, Shruthi, N. R.,, Sun, Xiao-Feng,, Ganesan, Harsha,, Banerjee, Antara,, Jain, M. Samatha,, Pathak, Surajit,   +11 more
core   +2 more sources

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy

BMC Cancer, 2022
Background Platinum chemoresistance results in high-grade serous ovarian cancer (HGSOC) disease recurrence. Recent treatment advances using checkpoint inhibitor immunotherapy has not benefited platinum-resistant HGSOC.
Michelle W. Wong-Brown, Andre van der Westhuizen, Nikola A. Bowden   +2 more
doaj   +1 more source

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers

Pharmacology Research & Perspectives, 2021
Trial data support an absence of an exposure–survival relationship for pembrolizumab. As these relationships remain unexamined in a real‐world setting, we determined them in metastatic melanoma prospectively in an observational study.
Vishal Navani, Moira C. Graves, Giovana Celli Marchett, Hiren Mandaliya, Nikola A. Bowden, Andre van derWesthuizen   +5 more
doaj   +1 more source